Grafts of extra-adrenal chromaffin cells as aggregates show better survival rate and regenerative effects on parkinsonian rats than dispersed cell grafts

Neurobiology of Disease

Volumn 29, Issue 3, 2008, Pages 529-542

  Galan Rodriguez, B ^a   del Marco, A ^a   Flores, J A ^a   Ramiro Fuentes, S ^a   Gonzalez Aparicio, R ^a   Tunez, I ^b   Tasset, I ^b   Fernandez Espejo, E ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

^b UNIVERSITY OF CÓRDOBA   (Spain)

Author keywords

Extra adrenal; GDNF; Graft; Parkinson; Regeneration; TGF 1; Trophic; Zuckerkandl's paraganglion

Indexed keywords

DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; TRANSFORMING GROWTH FACTOR BETA1;

ADRENAL GLAND; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL AGGREGATION; CELL DEGENERATION; CELL DISPERSED; CELL FUNCTION; CELL REGENERATION; CELL THERAPY; CELL TRANSPLANTATION; CHROMAFFIN CELL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; MALE; MOTOR DYSFUNCTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NORADRENERGIC SYSTEM; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; RAT; REGENERATION; SPROUTING; SURVIVAL RATE; VENTRAL TEGMENTUM; WISTAR RAT; ZUCKERKANDL PARAGANGLION;

ANIMALS; CELLS, CULTURED; CHROMAFFIN CELLS; CORPUS STRIATUM; GRAFT SURVIVAL; MALE; PARA-AORTIC BODIES; PARAGANGLIA, CHROMAFFIN; PARKINSONIAN DISORDERS; RATS; RATS, WISTAR; TRANSPLANTS;

EID: 39249084874     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2007.11.009     Document Type: Article

References (56)

1. Abercrombie M. Estimation of nuclear population from microtome sections. Anat. Rec. 94 (1946) 239-247
2. Ahonen M., Soinila S., and Joh T.H. Pre- and postnatal development of rat retroperitoneal paraganglia. J. Auton. Nerv. Syst. 18 (1987) 111-120
3. Bankiewicz K.S., Palmatie M., Plunkett R.J., Cummins A., and Oldfield E.H. Reversal of hemiparkinsonian syndrome in nonhuman primates by amnion implantation into caudate nucleus. J. Neurosurg. 81 (1994) 869-876
4. Batchelor P.E., Liberatore G.T., Wong J.Y.F., Porritt M.J., Frerichs F., Donnan G.A., and Howells D.W. Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J. Neurosci. 19 (1999) 1708-1716
5. Batchelor P.E., Liberatore G.T., Porritt M.J., Donnan G.A., and Howells D.W. Inhibition of brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor expression reduces dopaminergic sprouting in the injured striatum. Eur. J. Neurosci. 12 (2000) 3462-3468
6. Beck K.D., Valverde J., Alexi T., Poulsen K., Moffat B., Vandlen R.A., Rosenthal A., and Hefti F. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 373 (1995) 339-341
7. Bohn M.C., Goldstein M., and Black I.B. Expression of phenylethanolamine N-methyltransferase in rat sympathetic ganglia and extra-adrenal chromaffin tissue. Dev. Biol. 89 (1982) 299-308
8. Bohn M.C., Cupit L.C., Marciano F., and Gash D.M. Adrenal medullary grafts enhance recovery of striatal dopaminergic fibers. Science 237 (1987) 913-916
9. Bolam J.P., Freund T.F., Björklund A., Dunnett S.B., and Smith A.D. Synaptic input and local output of dopaminergic neurons in grafts that functionally reinnervate the host striatum. Exp. Brain Res. 68 (1987) 131-146
10. Bresjenac M., Sagen J., Seigel G., Paino C.L., Kordower J., and Gash D.M. Xenogenic adrenal medulla graft rejection rather than survival leads to increased rat striatal tyrosine hydroxylase immunoreactivity. J. Neuropathol. Exp. Neurol. 56 (1997) 490-498
11. Brundin P., and Björklund A. Survival of expanded dopaminergic precursors is critical for clinical trials. Nat. Neurosci. 1 (1998) 537
12. Dunnett S.B., and Björklund A. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 399 (1999) A32-A39
13. El Banoua F., Caraballo I., Flores J.A., Galan-Rodriguez B., and Fernandez-Espejo E. Effects on turning of microinjections into basal ganglia of D1 and D2 dopamine receptors agonists, and the cannabinoid CB1 antagonist SR141716A in a rat Parkinson's model. Neurobiol. Dis. 16 (2004) 377-385
14. Ericson C., Georgievska B., and Lundberg C. Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's disease. Eur. J. Neurosci. 22 (2005) 2755-2764
15. Espejo E.F., Montoro R.J., Armengol J.A., and Lopez-Barneo J. Cellular and functional recovery of parkinsonian rats after intrastriatal transplantation of carotid body cell aggregates. Neuron 20 (1998) 197-206
16. 1-expressing extra-adrenal chromaffin cells of the Zuckerkandl's organ. J. Neurosci. 21 (2001) 9888-9895
17. Fernandez-Espejo E., Armengol J.A., Flores J.A., Galan-Rodriguez B., and Ramiro S. Cells of the sympathoadrenal lineage: biological properties as donor tissue for cell-replacement therapies for Parkinson's disease. Brain Res. Rev. 49 2 (2005) 343-354
18. Freed W.J., Morihisa J.M., Spoor E., Hoffer B.J., Olson L., Seiger A., and Wyatt R.J. Transplanted adrenal chromaffin cells in rat brain reduce lesion-induced rotational behavior. Nature 292 (1981) 351-352
19. Gash D.M., Zhang Z.M., and Gerhardt G. Neuroprotective and neurorestorative properties of GDNF. Ann. Neurol. (Suppl) 44 (1998) G121-S125
20. Goetz C.G., Stebbins G.T., Klawans H.L., Holler W.C., Grossman R.G., Bakay R.A., and Penn R.D. United Parkinson Foundation neurotransplantation registry on adrenal medullary transplants presurgical, and 1-year and 2-year follow-up. Neurology 41 (1991) 1719-1722
21. Hagg T. Neurotrophins prevent death and differentially affect tyrosine hydroxylase of adult rat nigrostriatal neurons in vivo. Exp. Neurol. 149 (1998) 183-192
22. Kirik D., Rosenblad C., Björklund A., and Mandel R.J. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J. Neurosci. 20 (2000) 4686-4700
23. Kohn A. Die paraganglien. Arch. Mikrosk. Anat. 52 (1903) 262-365
24. Krieglstein K., Henheik P., Farkas L., Jaszai J., Galter D., Krohn K., and Unsicker K. Glia cell line-derived neurotrophic factor requires transforming growth factor-beta for exerting its full neurotrophic potential on peripheral an CNS neurons. J. Neurosci. 18 (1998) 9822-9834
25. Krieglstein K., Reuss B., Maysinger D., and Unsicker K. Transforming growth factor-beta mediates the neurotrophic effect of fibroblast growth factor-2 on midbrain dopaminergic neurons. Eur. J. Neurosci. 10 (1998) 2746-2750
26. Li X., Peng C., Li L., Ming M., Yang D., and Le W. Glial cell-derived neurotrophic factor protects against proteasome inhibition-induced dopamine neuron degeneration by suppression of endoplasmic reticulum stress and caspase-3 activation. J. Gerontol. A. Biol. Sci. Med. Sci. 62 9 (2007) 943-950
27. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., and Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260 (1993) 1130-1132
28. 3H]N-methylspiperone binding. J. Neurochem. 48 (1987) 631-635
29. McNaught K.S., Mytilineou C., Jnobaptiste R., Yabut J., Shashidharan P., Jennert P., and Olanow C.W. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J. Neurochem. 81 2 (2002) 301-306
30. Nakao N., Itakura T., Uematsu Y., and Komai N. Transplantation of cultured sympathetic ganglionic neurons into parkinsonian rat brain: survival and function of graft. Acta Neurochir. 133 (1995) 61-67
31. O'Connor D.T. Chromaffin cell mechanisms: understanding catecholamine storage and release. Trends Pharmacol. Sci. 20 (1999) 431-432
32. Paxinos G. The Rat Nervous System (1995), Academic Press, San Diego
33. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (2005), Elsevier, Amsterdam
34. Peterziel H., Unsicker K., and Krieglstein K. TGFbeta induces GDNF responsiveness in neurons by recruitment of GFRalpha1 to the plasma membrane. J. Cell Biol. 159 1 (2002) 157-167
35. Pupilli C., Lanzillotti R., Fiorelli G., Selli C., Gomez R.A., Carey R.M., Serio M., and Mannelli M. Dopamine D2 receptors gene expression and binding sites in adrenal medulla and pheocromocytoma. J. Clin. Endocrinol. Metab. 79 (1994) 56-61
36. Przedborski S., Levivier M., Jiang H., Ferreira M., Jackson L.V., Donaldson D., and Togasaki D.M. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 67 (1995) 631-647
37. Salvatore M.F., Zhang J.L., Large D.M., Wilson P.E., Gash C.R., Thomas T.C., Haycock J.W., Bing G., Stanford J.A., Gash D.M., and Gerhardt G.A. Striatal GDNF administration increases tyrosine hydroxylase phosphorylation in the rat striatum and substantia nigra. J. Neurochem. 90 (2004) 245-254
38. Sauer H., and Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59 (1994) 401-415
39. Schober A., Hertel R., Arumae U., Farkas L., Jaszai J., Krieglstein K., Saarma M., and Unsicker K. Glial cell line-derived neurotrophic factor rescues target-deprived sympathetic spinal cord neurons but requires transforming growth factor-beta as cofactor in vivo. J. Neurosci. 19 (1999) 2008-2015
40. Schober A., Peterziel H., von Bartheld C.S., Simon H., Krieglstein K., and Unsicker K. GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-beta for its neuroprotective action. Neurobiol. Dis. 25 2 (2007) 378-391
41. Schwarting R.K.W., and Huston J.P. The unilateral 6-hydroxydopamine lesion model in behavioral brain research: analysis of functional deficits, recovery and treatments. Prog. Neurobiol. 50 (1996) 275-331
42. Studer L., Tabar V., and McKay R.D. Transplantation of expanded mesencephalic precursors leads to recovery in parkinsonian rats. Nat. Neurosci. 1 (1998) 290-295
43. Testut L., and Latarjet A. Tratado de anatomia humana (1978), Salvat, Barcelona
44. Tian H., McKnight S.L., and Russell D.W. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 11 (1997) 72-82
45. Tischler A.S. The adrenal medulla and extra-adrenal paraganglia. In: Kovacs K., and Asa S.L. (Eds). Functional Endocrine Pathology (1990), Blackwell, Cambridge MA 12-24
46. Tischler A.S. Chromaffin cells as models of endocrine cells and neurons. Ann. N.Y. Acad. Sci. 971 (2002) 366-370
47. Tomac A., Lindqvist E., Lin L.F., Ogren S.O., Young D., Hoffer B.J., and Olson L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373 (1995) 335-339
48. Tseng J.L., Baetge E.E., Zurn A.D., and Aebisher P. GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanisms not involving striatal dopamine. J. Neurosci. 17 (1997) 325-333
49. Ungerstedt U., and Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res. 24 (1970) 486-493
50. Unsicker K. The trophic cocktail made by adrenal chromaffin cells. Exp. Neurol. 123 (1993) 167-173
51. Unsicker K., and Krieglstein K. Bovine chromaffin cells release a transforming growth factor-beta-like molecule contained within chromaffin granules. J. Neurochem. 65 (1995) 1423-1426
52. Unsicker K., and Krieglstein K. Growth factors in chromaffin cells. Prog. Neurobiol. 48 (1996) 307-324
53. Unsicker K., Suter-Crazzolara C., and Krieglstein K. Growth factors function in the development and maintenance of midbrain dopaminergic neurons: concepts, facts and prospects for TGF-β. Ciba Found. Symp. 196 (1996) 70-80
54. Villadiego J., Mendez-Ferrer S., Valdez-Sanchez T., Silos-Santiago I., Farinas I., Lopez-Barneo J., and Toledo-Aral J.J. Selective glial cell line-derived neurotrophic factor production in adult dopaminergic carotid body cells in situ and after intrastriatal transplantation. J. Neurosci. 25 16 (2005) 4091-4098
55. Wider C., Burkhard P.R., Sajadi A., and Vingerhoets F.J. Neuronal death and growth factors: new therapeutic approaches in Parkinson's disease. Rev. Méd. Suisse Romande 2 (2006) 1158-1162
56. Xu R.Y., Pong K., Yu Y., Chang D., Liu S., Lile J.D., Treanor J., Beck K.D., and Louis J.C. Characterization of two distinct monoclonal antibodies specific for glial cell line-derived neurotrophic factor. J. Neurochem. 70 (1998) 1383-1393